

EUROPEAN  
CURRICULUM VITAE  
FORMAT



PERSONAL INFORMATION

Name **MICHELE DEL VECCHIO**  
Home address  
Job address:

Telephone  
Fax  
E-mail

Nationality **Italian**

Date and Place of birth

## WORK EXPERIENCE

- In 1986-87, I attended the Department of Normal Human Anatomy, where I assisted, as *tutor*, the students of the first year of the course in Medicine and Surgery, regarding the anatomy of the heart during the autopsies.  
  
During the University years 1987-88 and 1988-89, I attended the Departments of General Pathology, Immunology and Experimental Oncology.
- From November 1989 to November 1992, I attended the Department of Internal Medicine, participating to clinical-experimental studies of immunology and immunopathology
- In 1993 I won a fellowship of the A.I.L. (Italian Association for Leukemia), which allowed me to work in the lab of Immunology of the Department of Oncology of the University of Padua on research projects regarding cancer immunotherapy and chemoimmunotherapy. In particular, I performed a research regarding the antitumor efficacy, in murine models, of the LAK cells loaded with toxins (Ricin-A) or with antitumor drugs (Antracyclins). Then, I took part to the initial studies on the use of LAK cells loaded with antitumor antibiotics and vehicled to the tumor by bifunctional monoclonal antibodies
- In December 1993 I ended the work related to my fellowship: “ *LGL (large granular lymphocytes) lymphoproliferative disease with particular regard to the role of the Protein-Tyrosin-Kinase (PTK) in the cytotoxic activity of the (CD3+; CD3-) LGL populations* ”
- In 1994 I was offered a fellowship from the Tumor Institute “F. Addarii” of Bologna, directed by Prof. C. Maltoni
- From January 1994 to December 1997 I attended the School of Specialty in Oncology at the University of Milan for the Division of Medical Oncology of the Istituto Nazionale Tumori, directed by Prof. E. Bajetta
- I was involved in research programs of the Medical Oncology B Division regarding the treatment and data processing of several different study protocols on melanoma, gastrointestinal tumors, kidney and breast cancer
- Since 1996 I have been the Responsible Investigator of several Italian and International trials on melanoma, both in adjuvant and metastatic settings
- I performed, as Responsible Investigator, the trial “*Pilot Study of weekly subcutaneous administration of Interleukin-12 (RO 24-7472) in patients with advanced/metastatic melanoma*”. I presented the data of this study at the ASCO Conference held in Philadelphia on May 21, 1996 (oral presentation).
- In the Summer of 1996 I attended, as *visiting researcher*, the Department of Surgery and Biologic Therapies of the Pittsburgh Cancer Institute, directed by Prof. M.T. Lotze.
- Following the requested exams (written and oral), I was accepted for the 1998 PhD programme of the Open University of London, presenting a research project titled: “*Generation and use of genetically modified HLA-A2-compatible allogeneic melanoma cells to express B7.1 costimulatory molecule and to release IL-2*”. Tutors: G. Parmiani, Director of the Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, and F. Balkwill, Imperial Cancer Research Fund., London.

- I contributed to develop the Guidelines and to write the booklet for the treatment of melanoma of the Istituto Nazionale Tumori of Milan (Malignant Melanoma Booklet, I.N.T. Milan, 1998; E-Book Melanoma, I.N.T. Milan, 2002).
- From January 1998 to January 2000, fellowship for the Ph.D. programme at the Unit of Immunotherapy of Human Tumors, Istituto Nazionale Tumori, Milan, directed by Dr. G. Parmiani.
- From June 1999 to May 2001 activity of Consultancy for the Pharmaceutical Company ASTA MEDICA.
  - In June 2000 I obtained grants for a post-doctoral position (visiting research associate) at the University of Pittsburgh (Pittsburgh Cancer Institute).
  - Since June 2000, fixed position of “Dirigente Medico di I Livello” at the Unit of Medical Oncology 2 , directed by Prof. E. Bajetta, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan.
  - Since 2003 activity of Consultancy, as expert on melanoma, for the following Pharmaceutical Companies: Chiron, Schering-Plough, Italfarmaco and Aventis.
    - I carried-out the “Italian multicenter randomized phase III trial comparing polychemotherapy ( CVD regimen – Cisplatin/Vindesine/Dacarbazine) with the same chemotherapy in combination with IFN- $\alpha$ 2b/IL-2-based immunotherapy as first-line treatment of metastatic melanoma. I presented the study results at the ASCO Conference held in Chicago from May 31 to June 3, 2003 (oral presentation).
    - I wrote a research protocol regarding the use of fotemustine and Bevacizumab as first-line therapy of metastatic melanoma patients (a phase II trial)”, which was approved and, consequently, supported by Roche, USA.
    - From February 2007 to January 2008 I attended the Cell and Gene Therapy Department of the Baylor College of Medicine, Houston and the Melanoma Medical Oncology Department of the M.D. Anderson Cancer Center (MDACC), Houston (TX), USA
- From June 1999 to May 2001 activity of Consultancy for the Pharmaceutical Company ASTA MEDICA.
- In June 2000 I obtained grants for a post-doctoral position (visiting research associate) at the University of Pittsburgh (Pittsburgh Cancer Institute).
- Since June 2000, fixed position of “Dirigente Medico di I Livello” at the Unit of Medical Oncology 2 , directed by Prof. E. Bajetta, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan.
- Since 2003 activity of Consultancy, as expert on melanoma, for the following Pharmaceutical Companies: Chiron, Schering-Plough, Italfarmaco and Aventis.
- I carried-out the “Italian multicenter randomized phase III trial comparing polychemotherapy ( CVD regimen – Cisplatin/Vindesine/Dacarbazine) with the same chemotherapy in combination with IFN- $\alpha$ 2b/IL-2-based immunotherapy as first-line treatment of metastatic melanoma. I presented the study results at the ASCO Conference held in Chicago from May 31 to June 3, 2003 (oral presentation).
- I wrote a research protocol regarding the use of fotemustine and Bevacizumab as first-line therapy of metastatic melanoma patients (a phase II trial)”, which was approved and, consequently, supported by Roche, USA.
- From February 2007 to January 2008 I attended the Cell and Gene Therapy Department of the Baylor College of Medicine, Houston and the Melanoma Medical Oncology Department of the M.D. Anderson Cancer Center (MDACC), Houston (TX), USA

## EDUCATION AND TRAINING

• Dates (from – to)

- July 1985 – Classic High School Diploma, Istituto “F. De Sanctis”, Trani (Bari), Italy (60/60).
- After having passed the admission examination, I attended the “Università Cattolica del Sacro Cuore (Policlinico Gemelli)”, Rome, and obtained the Degree in Medicine and Surgery on 19/10/1992: 110/110.  
Clinical-experimental thesis titled “Hematophagic Histiocytosis: *revision of the literature and clinic-pathologic contribution*”, prepared at the Department of Internal Medicine of the over mentioned University (Tutors: Prof. G. Gambassi and Dr. R. Manna).
- Licensure at the Medical professional activity obtained on November 1992 at the Università Cattolica in Rome.
- Specialty in Oncology obtained in November 1997, 70/70 cum laude, at the University of Milan, presenting a clinical-experimental thesis titled “*Use of Interleukin-12 in the treatment of metastatic melanoma*” (Tutors: Prof. E. Clerici, Prof. E. Bajetta).
- I passed step 1 and step 2, currently step 2CK of the U.S.M.L.E. examinations requested for getting the E.C.F.M.G. Certification necessary for the licensure of the medical activity in the U.S.
- I obtained the European Certification in Medical Oncology (E.S.M.O.), after passing the examination held in Vienna (Austria) on September 12, 1999.
- In 2001 I passed the TOEFL *testing* (English language proficiency test)

- Name and type of organisation providing education and training
- Principal subjects/occupational skills covered
  - Title of qualification awarded
- Level in national classification (if appropriate)

## PERSONAL SKILLS AND COMPETENCES

*Acquired in the course of life and career but not necessarily covered by formal certificates and diplomas.*

### MOTHER TONGUE

ITALIAN

### OTHER LANGUAGES

#### ENGLISH

- Reading skills
- Writing skills
- Verbal skills

level: excellent  
level: excellent  
level: excellent

## SOCIAL SKILLS AND COMPETENCES

*Living and working with other people, in multicultural environments, in positions where communication is important and situations where teamwork is essential (for example culture and sports), etc.*

- Since June 1994, member of AIOM (Italian Association of Medical Oncology)
- Since May 1996, member of ESMO (European Society for Medical Oncology)
- Since April 2000, member of ASCO (American Society of Clinical Oncology)
- Since 2004 - present –Founding Member of the “Society for Melanoma Research”.

**ORGANISATIONAL SKILLS  
AND COMPETENCES**

*Coordination and administration of people, projects and budgets; at work, in voluntary work (for example culture and sports) and at home, etc.*

[ Describe these competences and indicate where they were acquired. ]

**TECHNICAL SKILLS  
AND COMPETENCES**

*With computers, specific kinds of equipment, machinery, etc.*

Computer Practice: ability to use Office Programs  
Optimal knowledge of use of Internet and electronic mail

**ARTISTIC SKILLS  
AND COMPETENCES**

*Music, writing, design, etc.*

[ Describe these competences and indicate where they were acquired. ]

**OTHER SKILLS  
AND COMPETENCES**

*Competences not mentioned above.*

Author and co-author of several publications on Medical Oncology in English and Italian

**DRIVING LICENCE(S)**

Driving License type B

**ADDITIONAL INFORMATION**

[ Include here any other information that may be relevant, for example contact persons, references, etc. ]

**REGISTER OF PHYSICIAN**

25/02/2002; subscription number: 37655

**LAST GCP TRAINING**

Involved in international clinical trials according to ICH-GCP principles

**LAST TRIALS EXPERIENCE**

Indication	Study Phase	Year of study	Total # patients randomised
Melanoma m+	III	2008	8
NSCLC	II	2008	10 on going
Colorectal cancer	II	2008	8 on going

**ANNEXES**

- List of Publications
- List of Abstracts
- List of Books
- List of teaching and congress activities

***I hereby authorize the treatment of my personal data  
in accordance with the terms of  
Legislative Decree 196/03***

Milan, 10/07/2014

Name and Family Name (signature)

